Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 201–300 of 1,001
Stewart, D. J., & Kurzrock, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9621 · Cited by 104
Puzanov, I. J., Lindsay, C. R., Goff, L. W., Sosman, J. A., Gilbert, J., Berlin, J. D., Poondru, S., Simantov, R., Gedrich, R., Stephens, A. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0303 · Cited by 104
Mao, C., Huang, Y., Yang, Z., Zheng, D., Chen, J., & Tang, J. (2013) · Cancer · doi:10.1002/cncr.27804 · Cited by 99
Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma
Dueck, G., Chua, N. S., Prasad, A., Finch, D. L., Stewart, D., White, D. J., van der Jagt, R., Johnston, J. B., Belch, A. R., & Reiman, T. (2010) · Cancer · doi:10.1002/cncr.25377 · Cited by 99
Sood, A., McClain, D., Maitra, R., Basu-Mallick, A., Seetharam, R., Kaubisch, A., Rajdev, L., Mariadason, J. M., Tanaka, K., & Goel, S. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.12.001 · Cited by 98
Richardson, P. G. G., Eng, C., Kolesar, J., Hideshima, T., & Anderson, K. C. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.681376 · Cited by 101
Rocca, Y. S., Roberti, M. P., Juliá, E. P., Pampena, M. B., Bruno, L., Rivero, S., Huertas, E., Sánchez Loria, F., Pairola, A., Caignard, A., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00413 · Cited by 97
MicroRNAs in the DNA Damage/Repair Network and Cancer
Tessitore, A., Cicciarelli, G., Vecchio, F. D., Gaggiano, A., Verzella, D., Fischietti, M., Vecchiotti, D., Capece, D., Zazzeroni, F., & Alesse, E. (2014) · International Journal of Genomics · doi:10.1155/2014/820248 · Cited by 107
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110
Biomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 105
Debucquoy, A., Haustermans, K. M., Daemen, A., Aydın, S., Libbrecht, L. J., Gevaert, O., Moor, B. D., Tejpar, S., McBride, W. H., PENNINCKX, F. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5033 · Cited by 103
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka-Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 96
Pfeiffer, P., Nielsen, D. L., Bjerregaard, J. K., Qvortrup, C., Yilmaz, M. K., & Jensen, B. V. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn020 · Cited by 98
Hickey, R., Lewandowski, R. J., Prudhomme, T., Ehrenwald, E., Baigorri, B., Critchfield, J., Kallini, J. R., Gabr, A., Gorodetski, B., Geschwind, J.-F., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.166082 · Cited by 104
Hazama, S., Nakamura, Y., Takenouchi, H., Suzuki, N., Tsunedomi, R., Inoue, Y., Tokuhisa, Y., Iizuka, N., Yoshino, S., Takeda, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-63 · Cited by 93
“Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death in industrialized countries [1].”
BackgroundResultInfluentialInteraction of Radiation Therapy With Molecular Targeted Agents
Morris, Z. S., & Harari, P. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1366 · Cited by 93
Therapeutic strategy in unresectable metastatic colorectal cancer
Chibaudel, B., Tournigand, C., André, T., & de Gramont, A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011431592 · Cited by 103
André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds465 · Cited by 98
Morse, M. A., Chaudhry, A., Gabitzsch, E. S., Hobeika, A. C., Osada, T., Clay, T. M., Amalfitano, A., Burnett, B. K., Devi, G. R., Hsu, D. S., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1400-3 · Cited by 104
“By engaging the patient’s immune system, active immunotherapeutics, such as Ad5 [E1-, E2b-]-CEA(6D), could induce continuous immunologic anti-tumor responses over a long period of time that could result in a ‘‘deceleration’’ or alteration in specific aspects of the rapid growth rate or spread of the tumor not measured…”
BackgroundPredictive biomarker validation in practice: lessons from real trials
Mandrekar, S. J., & Sargent, D. J. (2010) · Clinical Trials · doi:10.1177/1740774510368574 · Cited by 101
Ferreira, J. A., Magalhães, A., Gomes, J., Peixoto, A., Gaiteiro, C., Fernandes, E., Santos, L. L., & Reis, C. A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.044 · Cited by 107
Lacouture, M. E., Anadkat, M. J., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. P. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.004 · Cited by 110
“Evidence has also shown that the incidence and severity of dermatologic toxicity can be influenced by the addition of chemotherapy.(2,4,5,23,28) New approaches to the management of skin toxicity have been used, such as the introduction of novel therapeutic agents and the use of preemptive treatment approaches based”
BackgroundS3 Guidelines for Colorectal Carcinoma
Schmiegel, W., Pox, C. P., Reinacher-Schick, A. C., Adler, G., Arnold, D., Fleig, W. E., Fölsch, U. R., Frühmorgen, P., Graeven, U., Heinemann, V., et al. (2010) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0028-1109936 · Cited by 120
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.606213 · Cited by 92
Lewandowski, R. J., Memon, K., Mulcahy, M. F., Hickey, R., Marshall, K., Williams, M., Salzig, K., Gates, V. L., Atassi, B., Vouche, M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2799-2 · Cited by 93
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Köhne, C.-H., & Lenz, H.-J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0202 · Cited by 90
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 103
Tabernero, J. M., Ciardiello, F., Rivera, F., Rodríguez-Braun, E., Ramos, F. J., Martinelli, E., Vega-Villegas, M. E., Roselló, S., Liebscher, S., Kisker, O., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp549 · Cited by 99
Kao, J., Packer, S. H., Vu, H. L., Schwartz, M., Sung, M. W., Stock, R. G., Lo, Y., Huang, D., Chen, S., & Cesaretti, J. A. (2009) · Cancer · doi:10.1002/cncr.24412 · Cited by 91
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
van de Haar, J., Ma, X., Ooft, S. N., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 83
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy
Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09096-8 · Cited by 106
Steele, N., Anthony, A., Saunders, M., Esmarck, B., Ehrnrooth, E., Kristjansen, P. E. G., Nihlén, A., Hansen, L. T., & Cassidy, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.599 · Cited by 87
Panitumumab: A Review of its Use in Metastatic Colorectal Cancer
Keating, G. M. (2010) · Drugs · doi:10.2165/11205090-000000000-00000 · Cited by 102
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Wang, H. L., Lopategui, J. R., Amin, M. B., & Patterson, S. D. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c6962f · Cited by 99
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Jonker, D. J., Karapetis, C. S., Harbison, C., O'Callaghan, C. J., Tu, D., Simes, R. J., Malone, D. P., Langer, C., Tebbutt, N., Price, T. J., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.753 · Cited by 88
“…Gastro-Intestinal Trials Group (AGITG), cetuximabþ best supportive care (BSC) improves overall survival (OS) and progression-free survival (PFS), and better preserves quality of life for advanced chemotherapy–refractory colorectal cancer compared with BSC alone (Au et al, 2009; Jonker et al, 2007).”
BackgroundSelf-citationEpidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 104
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 85
Benson, A. B., Geschwind, J.-F. H., Mulcahy, M. F., Rilling, W. S., Siskin, G. P., Wiseman, G., Cunningham, J. C., Houghton, B., Ross, M., Memon, K., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.012 · Cited by 90
Pietrantonio, F., Cremolini, C., Petrelli, F., Bartolomeo, M. D., Loupakis, F., Maggi, C., Antoniotti, C., de Braud, F., Falcone, A., & Iacovelli, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.016 · Cited by 99
Minasian, L. M., Carpenter, W. R., Weiner, B. J., Anderson, D. E., McCaskill‐Stevens, W., Nelson, S., Whitman, C., Kelaghan, J., O'Mara, A. M., & Kaluzny, A. D. (2010) · Cancer · doi:10.1002/cncr.25248 · Cited by 86
Tsimberidou, A.-M., Braiteh, F., Stewart, D. J., & Kurzrock, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6018 · Cited by 87
Consensus-based standards for best supportive care in clinical trials in advanced cancer
Zafar, S. Y., Currow, D. C., Cherny, N. I., Strasser, F., Fowler, R., & Abernethy, A. P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70215-7 · Cited by 89
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Tan, A. C., Bagley, S. J., Wen, P. Y., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Wick, W., Chang, S. M., Galanis, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002459 · Cited by 95
Self-citationTian, L., Xu, B., Chen, Y., Li, Z., Wang, J., Zhang, J., Ma, R., Cao, S., Hu, W., Chiocca, E. A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00448-0 · Cited by 95
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 93
Helbling, D., Bodoky, G., Gautschi, O. P., Sun, H., Bosman, F. T., Gloor, B., Burkhard, R., Winterhalder, R., Madlung, A., Rauch, D., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds519 · Cited by 89
Oden-Gangloff, A., Di Fiore, F., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 84
“…rates in MCRC patients treated with anti-EGFR in monotherapy or in association with CT underlines the urgent need of predictive markers to select the appropriate patients who can benefit from these treatments (Cunningham et al, 2004; Saltz et al, 2004; Jonker et al, 2007; Van Cutsem et al, 2007).”
BackgroundInno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagalà, C., Cassano, A., Larocca, L. M., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.028 · Cited by 83
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., & Ciliberto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.550 · Cited by 86
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0521 · Cited by 84
Clinical trial designs incorporating predictive biomarkers
Renfro, L. A., Mallick, H., An, M., Sargent, D. J., & Mandrekar, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.008 · Cited by 92
Westwood, M. E., van Asselt, A. D. I., Ramaekers, B. L. T., Whiting, P. F., Joore, M. A., Armstrong, N., Noake, C., Ross, J., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18620 · Cited by 88
Wong, R., & Cunningham, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5024 · Cited by 92
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
Li, W., Qiu, T., Zhi, W., Shi, S., Zou, S., Ling, Y., Shan, L., Ying, J., & Lu, N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1345-3 · Cited by 79
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
Gui, T., & Shen, K. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.06.005 · Cited by 94
“colorectal cancer (mCRC) who are refractory to irinotecan in the USA and Europe in 2004 [33].”
BackgroundMultiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 85
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 78
Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
Cheng, H., Jiang, X., Zhang, Q., Ma, J., Cheng, R., Yong, H., Shi, H., Zhou, X., Ge, L., & Gao, G. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8649 · Cited by 79
Terzuoli, E., Giachetti, A., Ziche, M., & Donnini, S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500498 · Cited by 82
Adackapara, C., Sholl, L. M., Barletta, J. A., & Hornick, J. L. (2013) · Histopathology · doi:10.1111/his.12154 · Cited by 86
Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 91
Current Progress in Targeted Therapy for Colorectal Cancer
Ortega, J., Vigil, C. E., & Chodkiewicz, C. (2010) · Cancer Control · doi:10.1177/107327481001700102 · Cited by 85
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 86
Molecular Network of Colorectal Cancer and Current Therapeutic Options
Huang, Z., & Yang, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852927 · Cited by 96
“Currently, clinical studies have confirmed the beneficial effects of third-line treatment of metastatic CRC with Cetuximab in Australia and Europe (116, 117).”
BackgroundPander, J., Gelderblom, H. A. J., Antonini, N. F., Tol, J., van Krieken, J. H., van der Straaten, T., Punt, C. J. A., & Guchelaar, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.017 · Cited by 88
Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0239 · Cited by 93
Targeted therapies in colorectal cancer—an integrative view by PPPM
Hagan, S., Orr, M. C. M., & Doyle, B. J. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-3 · Cited by 101
Kim, C., Lee, J., Ryu, M., Chang, H. M., Kim, T. W., Lim, H. Y., Kang, H. J., Park, Y. S., Ryoo, B., & Kang, Y. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9363-0 · Cited by 82
“Cetuximab is a chimeric monoclonal antibody directed to the EGFR and approved for the use in advanced colorectal cancer and head and neck squamous cell carcinoma [1, 2, 4, 13].”
BackgroundEvaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
Gupta, A., O'Callaghan, C. J., Zhu, L., Jonker, D. J., Wong, R. P. W., Colwell, B., Moore, M. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00737 · Cited by 89
Self-citationPeeters, M., & Price, T. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.002 · Cited by 86
Self-citationMilenic, D. E., Wong, K. J., Baidoo, K. E., Ray, G. L., Garmestani, K., Williams, M. R., & Brechbiel, M. W. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0493 · Cited by 79
Nielsen, D. L., Palshof, J. A., Larsen, F. O., Jensen, B. V., & Pfeiffer, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.006 · Cited by 79
Overview of Systemic Therapy for Colorectal Cancer
Goodwin, R. A., & Asmis, T. R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242465 · Cited by 86
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Niraula, S., Amir, E., Vera-Badillo, F., Šeruga, B., Ocaña, A., & Tannock, I. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8437 · Cited by 81
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Zhang, P., Holowatyj, A. N., Roy, T., Pronovost, S. M., Marchetti, M., Liu, H., Ulrich, C. M., & Edgar, B. A. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.029 · Cited by 80
“, 2008), and in cancers with EGFR activation, EGFR-specific antibodies such as cetuximab can suppress cell growth by blocking ligand-induced receptor signaling (Jonker et al., 2007).”
BackgroundLiu, X., Adorno-Cruz, V., Chang, Y.-F., Jia, Y., Kawaguchi, M., Dashzeveg, N. K., Taftaf, R., Ramos, E. K., Schuster, E. J., El-Shennawy, L., et al. (2021) · Theranostics · doi:10.7150/thno.57706 · Cited by 89
Efficacy of Cetuximab in the Treatment of Ménétrier’s Disease
Fiske, W. H., Tanksley, J., Nam, K. T., Goldenring, J. R., Slebos, R. J. C., Liebler, D. C., Abtahi, A. M., Fleur, B. L., Ayers, G. D., Lind, C. D., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000320 · Cited by 81
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
Ku, G. Y., Tan, I. B., Yau, T. C. C., Boku, N., Laohavinij, S., Cheng, A., Kang, Y., & Lopes, G. D. L., Jr. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70424-2 · Cited by 79
Sastre, J., Grávalos, C., Rivera, F., Massutí, B., Valladares‐Ayerbes, M., Marcuello, E., Manzano, J. L., Benavides, M., Hidalgo, M. M., Díaz‐Rubio, E., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0406 · Cited by 77
Lorenzato, A., Magrì, A., Matafora, V., Audrito, V., Arcella, P., Lazzari, L., Montone, M., Lamba, S., Deaglio, S., Siena, S., et al. (2020) · Cancers · doi:10.3390/cancers12030685 · Cited by 79
“In a subset of advanced colorectal cancers (CRCs), treatment of RAS wild-type (wt) tumors with the anti-EGFR antibodies cetuximab or panitumumab leads to the killing of drug-sensitive cells and tumor volume reduction [1].”
Backgroundγδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors
Harmon, C., Zaborowski, A. M., Moore, H., Louis, P. S., Slattery, K., Duquette, D., Scanlan, J., Kane, H., Kunkemoeller, B. H., McIntyre, C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00589-w · Cited by 89
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
Iida, M., Brand, T. M., Starr, M. M., Li, C., Huppert, E. J., Luthar, N., Pedersen, M. W., Horak, I. D., Kragh, M., & Wheeler, D. L. (2013) · Neoplasia · doi:10.1593/neo.131584 · Cited by 75
Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., Tappenden, P., & Hyde, C. (2013) · Health Technology Assessment · doi:10.3310/hta17140 · Cited by 85
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review
Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572343 · Cited by 80
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
Arnold, D., Prager, G. W., Quintela, A., Stein, A., Vera, S. R. M., Mounedji, N., & Taïeb, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy038 · Cited by 76
Precision oncology: A new era of cancer clinical trials
Renfro, L. A., An, M.-W., & Mandrekar, S. J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.03.015 · Cited by 75
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 78
The Past, Present and Future of Pulmonary Metastasectomy: A Review Article
Cheung, F. P.-Y., Alam, N. Z., & Wright, G. M. (2019) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.ra.18-00229 · Cited by 77
Scartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25193 · Cited by 74
Targeting EGFR resistance networks in head and neck cancer
Ratushny, V., Astsaturov, I. A., Burtness, B. A., Golemis, E. A., & Silverman, J. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.021 · Cited by 83
Wang, J., Chen, B., Wang, Y., Tsai, Y.-T., Chen, W.-C., Chang, W., Hou, M., Wu, Y., & Chang, W.-C. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.017 · Cited by 75
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas
Fitz, C. D. V., Li, G., & Wong, A. J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.177 · Cited by 77
Nivolumab for the treatment of colorectal cancer
Smith, K. M., & Desai, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1480942 · Cited by 81
Zlobec, I., Vuong, T., Compton, C. C., Lugli, A., Michel, R. P., Hayashi, S., & Jass, J. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604172 · Cited by 74
Lawrence, Y. R., Vikram, B., Dignam, J. J., Chakravarti, A., Machtay, M. X., Freidlin, B., Takebe, N., Curran, W. J., Bentzen, S. M., Okunieff, P. G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs472 · Cited by 74
Cho, J., Pastorino, S., Zeng, Q., Xu, X., Johnson, W., Vandenberg, S., Verhaak, R., Cherniack, A. D., Watanabe, H., Dutt, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0821 · Cited by 74
Mao, C., Zhou, J., Yang, Z., Huang, Y., Wu, X., Shen, H., Tang, J., & Chen, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036653 · Cited by 75
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.